RxDoctor Payments Data

Ann Gordon, PA

Medical · Dallas, TXNPI 1588101000

Payments from drug & device makers

$6,506in general payments, 2019–2025

Across 47 payments — averaging $138.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Abbott$979
  • Medtronic$784
  • AstraZeneca$324
  • MDD US Operations, LLC$149
  • Johnson & Johnson$130
  • plus $576 from 6 others

What the payments were for

  • Travel & lodging$3,72157%
  • Food & beverage$2,75842%
  • Education$270%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,506 in reported general payments places this provider in the 85th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$38,729
Medicare patients
147
Services billed
868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa135$251,640
NuplazidPimavanserin Tartrate19$93,324
OngentysOpicapone20$20,751
Carbidopa-LevodopaCarbidopa/Levodopa136$9,762
Rasagiline Mesylate35$6,971
Carbidopa-Levodopa ErCarbidopa/Levodopa64$5,613
Mycophenolate Mofetil26$3,310
Ropinirole ErRopinirole Hcl11$3,246
AmantadineAmantadine Hcl37$2,728
Pyridostigmine Bromide24$2,536
Gabapentin38$1,414
Tetrabenazine12$1,316
Primidone24$1,264
Ipratropium Bromide20$466
Escitalopram Oxalate12$407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$115$257,486185 claims
Acadia Pharmaceuticals IncNuplazid$50$93,32419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,490 medical providers in Texas.

Other medical in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →